Toll Free: 1-888-928-9744

ASKA Pharmaceutical Co., Ltd. - Product Pipeline Review - 2014

Published: Dec, 2014 | Pages: 30 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)

ASKA Pharmaceutical Co., Ltd. - Product Pipeline Review - 2014

Summary

Global Markets Direct's, 'ASKA Pharmaceutical Co., Ltd. - Product Pipeline Review - 2014', provides an overview of the ASKA Pharmaceutical Co., Ltd.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of ASKA Pharmaceutical Co., Ltd.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of ASKA Pharmaceutical Co., Ltd. including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of ASKA Pharmaceutical Co., Ltd.'s human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones 
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement 
- Latest news and deals relating to the ASKA Pharmaceutical Co., Ltd.'s pipeline products

Reasons to buy

- Evaluate ASKA Pharmaceutical Co., Ltd.'s strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of ASKA Pharmaceutical Co., Ltd. in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the ASKA Pharmaceutical Co., Ltd.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of ASKA Pharmaceutical Co., Ltd. and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of ASKA Pharmaceutical Co., Ltd.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of ASKA Pharmaceutical Co., Ltd. and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues
 Table of Contents
Table of Contents 2
List of Tables 3
List of Figures 3
ASKA Pharmaceutical Co., Ltd. Snapshot 4
ASKA Pharmaceutical Co., Ltd. Overview 4
Key Information 4
Key Facts 4
ASKA Pharmaceutical Co., Ltd. - Research and Development Overview 5
Key Therapeutic Areas 5
ASKA Pharmaceutical Co., Ltd. - Pipeline Review 7
Pipeline Products by Stage of Development 7
Pipeline Products - Monotherapy 8
Pipeline Products - Partnered Products 9
Partnered Products/Combination Treatment Modalities 10
Pipeline Products - Out-Licensed Products 11
Out-Licensed Products/Combination Treatment Modalities 12
ASKA Pharmaceutical Co., Ltd. - Pipeline Products Glance 13
ASKA Pharmaceutical Co., Ltd. - Late Stage Pipeline Products 13
Phase III Products/Combination Treatment Modalities 13
ASKA Pharmaceutical Co., Ltd. - Clinical Stage Pipeline Products 14
Phase II Products/Combination Treatment Modalities 14
Phase I Products/Combination Treatment Modalities 15
ASKA Pharmaceutical Co., Ltd. - Drug Profiles 16
rifaximin 16
Product Description 16
Mechanism of Action 16
R&D Progress 16
AKP-501 18
Product Description 18
Mechanism of Action 18
R&D Progress 18
AKP-001 19
Product Description 19
Mechanism of Action 19
R&D Progress 19
ASKA Pharmaceutical Co., Ltd. - Pipeline Analysis 20
ASKA Pharmaceutical Co., Ltd. - Pipeline Products by Target 20
ASKA Pharmaceutical Co., Ltd. - Pipeline Products by Route of Administration 21
ASKA Pharmaceutical Co., Ltd. - Pipeline Products by Molecule Type 22
ASKA Pharmaceutical Co., Ltd. - Pipeline Products by Mechanism of Action 23
ASKA Pharmaceutical Co., Ltd. - Recent Pipeline Updates 24
ASKA Pharmaceutical Co., Ltd. - Dormant Projects 27
ASKA Pharmaceutical Co., Ltd. - Locations And Subsidiaries 28
Head Office 28
Appendix 29
Methodology 29
Coverage 29
Secondary Research 29
Primary Research 29
Expert Panel Validation 29
Contact Us 30
Disclaimer 30
List of Tables
ASKA Pharmaceutical Co., Ltd., Key Information 4
ASKA Pharmaceutical Co., Ltd., Key Facts 4
ASKA Pharmaceutical Co., Ltd. - Pipeline by Indication, 2014 6
ASKA Pharmaceutical Co., Ltd. - Pipeline by Stage of Development, 2014 7
ASKA Pharmaceutical Co., Ltd. - Monotherapy Products in Pipeline, 2014 8
ASKA Pharmaceutical Co., Ltd. - Partnered Products in Pipeline, 2014 9
ASKA Pharmaceutical Co., Ltd. - Partnered Products/ Combination Treatment Modalities, 2014 10
ASKA Pharmaceutical Co., Ltd. - Out-Licensed Products in Pipeline, 2014 11
ASKA Pharmaceutical Co., Ltd. - Out-Licensed Products/ Combination Treatment Modalities, 2014 12
ASKA Pharmaceutical Co., Ltd. - Phase III, 2014 13
ASKA Pharmaceutical Co., Ltd. - Phase II, 2014 14
ASKA Pharmaceutical Co., Ltd. - Phase I, 2014 15
ASKA Pharmaceutical Co., Ltd. - Pipeline by Target, 2014 20
ASKA Pharmaceutical Co., Ltd. - Pipeline by Route of Administration, 2014 21
ASKA Pharmaceutical Co., Ltd. - Pipeline by Molecule Type, 2014 22
ASKA Pharmaceutical Co., Ltd. - Pipeline Products by Mechanism of Action, 2014 23
ASKA Pharmaceutical Co., Ltd. - Recent Pipeline Updates, 2014 24
ASKA Pharmaceutical Co., Ltd. - Dormant Developmental Projects,2014 27 



                                

To request a free sample copy of this report, please complete the form below.

We never share your personal data. Privacy policy
Interested in this report? Get your FREE sample now! Get a Free Sample
Choose License Type
Single User - US $1500
Multi User - US $3000
Hexareeasearch Know

Did you know?

Research Assistance

Phone: 1-415-349-0054

Toll Free: 1-888-928-9744

Email: [email protected]

Why to buy from us

Custom research service

Speak to the report author to design an exclusive study to serve your research needs.

Information security

Your personal and confidential information is safe and secure.

verify